StockpollyBeta
Get App
Popularity #5,060
PASG · NASDAQ · Biotechnology

Passage Bio (PASG)

Winding down neurodegenerative gene therapies while pursuing a merger with Remix Therapeutics.

$5.00
vs last close+0.05 (+1.01%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000001000000
Gross profit00000−1000000
291818172114161091498
Research & development15121210910864543
867774654557
General & administrative867770654557
Other expenses50005030040−2
Operating income−29−18−18−17−21−14−16−10−9−14−9−8
221112111110
Interest income021111100000
Interest expense020000000000
Other non-operating income−5−3−10−5−1−3−1−1−4−10
Income before tax−27−17−17−16−19−13−15−9−8−13−8−8
Net income from continuing operations−27−17−17−16−19−13−15−9−8−13−8−8
Net income−27−17−17−16−19−13−15−9−8−13−8−8
EPS, basic−$9.90−$6.10−$5.94−$5.18−$6.26−$4.10−$4.96−$2.96−$2.45−$4.08−$2.36−$2.44
EPS, diluted−$9.90−$6.10−$5.94−$5.18−$6.26−$4.10−$4.96−$2.96−$2.45−$4.08−$2.36−$2.44
Weighted average shares, basic333333333333
Weighted average shares, diluted333333333333
EBITDA−22−14−16−16−15−12−14−9−7−10−7−8
Depreciation & amortization111111000000
EBIT−23−15−17−17−16−13−14−9−8−10−8−8